- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04261504
Brain Mechanisms of Reducing Polysubstance Use Following a Novel Body-mind Intervention
May 13, 2024 updated by: Texas Tech University
The proposed study will examine brain mechanisms of a brief mindfulness intervention - integrative body-mind training (IBMT) on alcohol, tobacco, and cannabis (ATC) reduction.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The R61 phase of the proposed study will examine brain mechanisms of a brief mindfulness intervention - integrative body-mind training (IBMT) that targets at self-control networks in the brain, and test IBMT effects on alcohol, tobacco, and cannabis (ATC) reduction.
Study Type
Interventional
Enrollment (Actual)
70
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Lubbock, Texas, United States, 79409
- TTU/UT
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 23 years (Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- (1) at least 18 years old;
- (2) free of any psychiatric diagnoses or medication (besides a substance use disorder to alcohol, tobacco, or cannabis);
- (3) in the past month, at least 4 episode of heavy episodic drinking; at least 3 occasion of cannabis use; and daily cigarette use for at least the past month;
- (4) normal or corrected-to-normal vision;
- (5) written informed consent;
- (6) no previous meditation or neurofeedback (NF) experiences.
Exclusion Criteria:
- (1) any psychiatric diagnoses other than a substance use disorder;
- (2) medical disorder(s) that may affect the central nervous system; medications that affect the central and autonomic nervous system; or a positive pregnancy test result (females);
- (3) excluding cannabis, evidence of recent (past month) illicit drug use.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Integrative Body Mind Training (IBMT)
mindfulness
|
mindful presence in a non-judgmental way
|
|
Active Comparator: Relaxation Training (RT)
relaxation
|
progressive muscle relaxation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Brain Changes in Functional Activity
Time Frame: The outcome measure is assessed at baseline and post-intervention.
|
70 participants with polysubstance use are assessed by changes of brain in functional activity of anterior cingulate cortex before (baseline) and post-intervention (2 weeks).
|
The outcome measure is assessed at baseline and post-intervention.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Yi-Yuan Tang, Texas Tech University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 19, 2019
Primary Completion (Actual)
February 28, 2023
Study Completion (Actual)
February 28, 2023
Study Registration Dates
First Submitted
December 22, 2019
First Submitted That Met QC Criteria
February 6, 2020
First Posted (Actual)
February 7, 2020
Study Record Updates
Last Update Posted (Actual)
May 29, 2024
Last Update Submitted That Met QC Criteria
May 13, 2024
Last Verified
May 1, 2024
More Information
Terms related to this study
Other Study ID Numbers
- IRB2018-943
- R61AT010138 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Drug Use
-
Arizona State UniversityRecruiting
-
Desitin Arzneimittel GmbHBioPharma Services, IncCompleted
-
Chestnut Health SystemsNational Institute on Drug Abuse (NIDA)Active, not recruitingPolysubstance Drug Use (Indiscriminate Drug Use)United States
-
University of California, Los AngelesInstituto Nacional de Psiquiatría Dr. Ramón de la FuenteCompletedDrug Use | Harmful Use
-
University of California, Los AngelesCompleted
-
University of California, Los AngelesNational Institute on Drug Abuse (NIDA); Medical University of South Carolina; University of ArkansasActive, not recruitingDrug UseUnited States
-
Hamad Medical CorporationPrimary Health Care Corporation, QatarActive, not recruiting
-
PT. Kimia Farma (Persero) TbkPT Pharma Metric LabsCompleted
-
PT BernofarmPT Pharma Metric LabsCompleted
-
Ain Shams UniversityRecruiting
Clinical Trials on IBMT
-
Arizona State UniversityRecruiting
-
Arizona State UniversityNational Center for Complementary and Integrative Health (NCCIH)Completed